Key Takeaways:

  • CMS has launched the voluntary BALANCE model to expand GLP-1 coverage in Medicare Part D and Medicaid through negotiated pricing with manufacturers
  • The coverage for weight loss under the BALANCE Model will launch in Medicaid as early as May 2026 and in Medicare Part D in January 2027
  • Eligible Medicare beneficiaries will pay $50 per month of GLP-1 medications through a bridge program starting July 2026
  • Participation is voluntary for manufacturers, states, and health plans, meaning coverage will vary by location

Trump Administration Unveils Major Policy Shift for GLP-1 Access

The Trump administration has announced a significant policy initiative that could transform access to GLP-1 weight loss medications for millions of Americans on government health plans. The Centers for Medicare & Medicaid Services (CMS) announced today a new voluntary test of a model that is designed to enable Medicare Part D plans and state Medicaid agencies to cover GLP-1 medications used for weight management and metabolic health improvement, while helping control costs for patients and taxpayers.

The Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth (BALANCE) Model represents the administration's alternative approach to addressing the coverage gap for obesity medications after the Trump administration reversed course on the previous administration's proposal to broadly expand Medicare coverage.

As part of this voluntary model, CMS will negotiate drug pricing and coverage terms with manufacturers of GLP-1 medications on behalf of state Medicaid agencies and Medicare Part D plan sponsors. This centralized negotiation approach aims to secure better pricing while maintaining voluntary participation for all stakeholders.

How the BALANCE Model Will Work

Unlike traditional coverage expansions that would require statutory changes, the BALANCE model operates as a demonstration project under CMS Innovation Center authority. Participation in BALANCE is voluntary for manufacturers, state Medicaid agencies, and Part D plans.

This model outlines how the administration plans to explore expanding access to obesity care with certain GLP-1 medications for people enrolled in Medicare and Medicaid. The model will also pair medication access with evidence-based lifestyle supports.

The timeline for implementation spans several years:

  • January 8, 2026: Application deadline for manufacturers
  • May 2026: BALANCE launches in participating Medicaid programs
  • July 2026: Medicare GLP-1 Bridge demonstration begins
  • January 2027: BALANCE launches in participating Medicare Part D plans
  • December 2031: Model testing concludes

Medicare Bridge Program Offers Immediate Relief

Recognizing the gap between current coverage limitations and the full BALANCE rollout, CMS has created an interim solution. Prior to the launch of the BALANCE model, CMS also plans to implement a new Medicare GLP-1 payment demonstration beginning in July 2026, which will serve as a short-term bridge to the model. This additional payment demonstration means that Medicare beneficiaries can start accessing these important medications at prices negotiated by the Administration as soon as possible.

The bridge program offers substantial cost savings for eligible beneficiaries. According to FAQs released by CMS in March 2026, Medicare beneficiaries enrolled in Part D plans who meet the eligibility criteria will have access to GLP-1 medications approved for weight reduction (Wegovy and Zepbound) at a copayment of $50 per month, while Manufacturers have agreed to provide Wegovy and Zepbound at a net price of $245 per month supply.

For context, these medications typically cost patients hundreds or even thousands of dollars monthly without coverage. The negotiated price represents a significant breakthrough in making these treatments accessible to Medicare beneficiaries who previously had few affordable options.

Policy Context: From Statutory Change to Innovation Model

The BALANCE model emerges after a complex policy evolution. On April 4, CMS announced its final rule changes for Medicare in the 2026 contract year. In the announcement, CMS stated it would not move forward with several provisions in the rule originally proposed in November, one of which was the proposed clause allowing for Medicare Part D coverage of obesity medications.

This reversal disappointed medical organizations and left advocates searching for alternative pathways. Robert W. Lash, MD, chief medical officer for the Endocrine Society, said the society stands behind CMS rules or legislation that would offer Medicare Part D coverage of obesity medications to all beneficiaries with the disease. The Obesity Society also released a statement saying it was disappointed in CMS's decision.

The BALANCE model represents a compromise approach that avoids the need for statutory changes while still expanding access for those in participating states and plans. However, its voluntary nature means coverage will be uneven across the country, creating a patchwork system where your zip code could determine your access to affordable treatment.

Cost and Budget Implications Drive Cautious Approach

The financial stakes remain significant even with the model's limited scope. Previous Congressional Budget Office analysis estimated that broader Medicare coverage would cost $1.5 billion in 2026 and by $6.1 billion in 2034 for an illustrative policy covering all eligible beneficiaries.

The voluntary nature of BALANCE may help control costs by allowing gradual rollout and testing of different approaches. For Medicaid, GLP-1 coverage will be expanded through the BALANCE Model beginning in May 2026. Only 13 states provided coverage as of January 2026, down from 16 states in 2025, likely reflecting the significant costs of coverage and recent state budget challenges and federal funding cuts.

This declining state participation underscores the budget pressures these medications create. States that do participate in BALANCE will benefit from CMS's negotiated pricing, potentially making coverage more sustainable long-term.

What This Means for You

The BALANCE model creates new opportunities for accessing affordable GLP-1 treatment, but coverage will depend heavily on where you live and which health plan you choose. If you're on Medicare Part D, the July 2026 bridge program could provide immediate access to semaglutide or tirzepatide at a monthly cost of $50 – representing savings of hundreds or thousands of dollars compared to current out-of-pocket expenses.

However, the voluntary nature means you'll need to research whether your state Medicaid program or Medicare plan chooses to participate. When selecting coverage for 2027 and beyond, participation in BALANCE should be a key factor in your decision-making process.

For those in non-participating plans or states, don't lose hope. You can explore telehealth providers that offer competitive pricing or find a clinic near you that provides affordable access to these medications. Our cost guide can help you compare options and find the most affordable path to treatment in your area.

The model also emphasizes lifestyle support alongside medication, which aligns with best practices for long-term success with GLP-1 treatments. This holistic approach could set a new standard for how these medications are prescribed and supported nationwide.